Scarica l'app Stockscreener
1.52
0.66%
0.01
Dopo l'orario di chiusura:
1.53
0.01
+0.66%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.51
Aprire:
$1.52
Volume 24 ore:
709.95K
Relative Volume:
0.76
Capitalizzazione di mercato:
$191.78M
Reddito:
-
Utile/perdita netta:
$-29.69M
Rapporto P/E:
-6.08
EPS:
-0.25
Flusso di cassa netto:
$-18.64M
1 W Prestazione:
+7.80%
1M Prestazione:
+10.95%
6M Prestazione:
-15.56%
1 anno Prestazione:
+106.38%
Intervallo 1D:
$1.49
$1.58
Intervallo di 1 settimana:
$1.35
$1.58
Portata 52W:
$0.62
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Nome
Atossa Therapeutics Inc
Settore
Industria
Telefono
206.588.0256
Indirizzo
10202 5TH AVENUE NE, SEATTLE, WA
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2018-01-26 | Iniziato | Maxim Group | Buy |
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Rhumbline Advisers Makes New $161,000 Investment in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Was Atossa Therapeutics Inc (ATOS)’s session last reading good? - US Post News
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp - Defense World
Atossa Therapeutics Inc [ATOS] Investment Guide: What You Need to Know - Knox Daily
What Has Been Going On With Atossa Therapeutics Inc (NASDAQ: ATOS) - Stocks Register
Atossa Therapeutics Inc (ATOS) can make a big difference with a little luck - SETE News
Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.41 - MarketBeat
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What is the investor’s view on Atossa Therapeutics Inc (ATOS)? - US Post News
Potential Price Increase for Atossa Therapeutics Inc (ATOS) After Recent Insider Activity - Knox Daily
Ratios Reveal: Breaking Down Atossa Therapeutics Inc (ATOS)’s Financial Health - The Dwinnex
Atossa Therapeutics Inc: Weathering Stock Market Storms with 182.35M Market Cap - The InvestChronicle
Taking on analysts’ expectations and winning: Atossa Therapeutics Inc (ATOS) - SETE News
Examining Atossa Therapeutics Inc (ATOS) stock is warranted - US Post News
Atossa Therapeutics (NASDAQ:ATOS) Price Target Increased to $6.50 by Analysts at Ascendiant Capital Markets - Defense World
Analyzing Atossa Therapeutics Inc (ATOS) After Recent Trading Activity - Knox Daily
Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $6.50 - MarketBeat
Atossa Therapeutics Inc’s Shares Reel: 21.67% Quarterly Revenue Decline Amid 183.61M Market Cap - The InvestChronicle
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer - StockTitan
Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Below 200-Day Moving Average of $1.38 - MarketBeat
Are Atossa Therapeutics Inc (ATOS) shares a good deal now? - US Post News
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Recent Insider Activity Suggests Potential Gains for Atossa Therapeutics Inc (ATOS) - Knox Daily
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice - Yahoo Finance
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
TSX Materials Capped Index (TTMT) QuotePress Release - The Globe and Mail
Atossa Therapeutics Inc (ATOS-Q) QuotePress Release - The Globe and Mail
Atossa secures new patent for breast cancer drug By Investing.com - Investing.com Canada
Atossa secures new patent for breast cancer drug - Investing.com
Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News
Atossa secures new patent for breast cancer drug By Investing.com - Investing.com UK
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen - Yahoo Canada Finance
Atossa Therapeutics Inc (ATOS) Stock: A Comprehensive 52-Week Review - The InvestChronicle
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Can you now get a good deal on Atossa Therapeutics Inc’s shares? - US Post News
The Potential Rise in the Price of Atossa Therapeutics Inc (ATOS) following insiders activity - Knox Daily
Financial Comparison: Atossa Therapeutics (NASDAQ:ATOS) versus Renovaro (NASDAQ:RENB) - Defense World
When Can We Expect A Profit From Atossa Therapeutics, Inc. (NASDAQ:ATOS)? - Simply Wall St
Atossa and Quantum Leap begin breast cancer treatment trial - Investing.com India
Understanding the Risks of Investing in Atossa Therapeutics Inc (ATOS) - Knox Daily
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - ForexTV.com
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - Yahoo Finance
Atossa and Quantum Leap begin breast cancer treatment trial By Investing.com - Investing.com Australia
Atossa and Quantum Leap begin breast cancer treatment trial - Investing.com
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - StockTitan
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations - StockTitan
Cetera Advisors LLC Takes $72,000 Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
FY2024 Earnings Estimate for Atossa Therapeutics, Inc. (NASDAQ:ATOS) Issued By Cantor Fitzgerald - Defense World
FY2024 EPS Estimates for Atossa Therapeutics, Inc. Lifted by Analyst (NASDAQ:ATOS) - MarketBeat
Atossa Therapeutics Inc Azioni (ATOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
4.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):